HMG-CoA reductase inhibitors and the risk of stroke. New mechanism(s) independent of cholesterol-lowering;HMG-CoA-reduktasehemmer und schlaganfallrisiko

Nervenarzt

Volumn 69, Issue 8, 1998, Pages 717-721

  Endres, M ^a,c   Laufs, U ^b,d  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Endothelial NO; HMG CoA reductase inhibitors; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; PROPHYLAXIS; RISK MANAGEMENT; STROKE;

ANIMALS; BRAIN; CEREBROVASCULAR DISORDERS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; NITRIC OXIDE SYNTHASE; UP-REGULATION; VASODILATION;

EID: 0031902335     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050335     Document Type: Article

References (42)

1. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P (1996) Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93:1647-1650
2. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332:488-393
3. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG (1997) Stroke, statins, and cholesterol. Ameta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28:946-950
4. Byington RP Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GB (1995) Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastain Atherosclerosis Intervention Program. Circulation 92:2419-2425
5. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E (1997) Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherosclerosis. Arterioscl Thromb Vase Biol 17:265-272
6. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD (1995) Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLACII). Am J Cardiol 75:455-459
7. Dalkara T, Moskowitz MA (1994) The complex role of nitric oxide in the pathophysiology of focal cerebral ischemia. Brain Pathol 4:49-57
8. Delanty N, Vaughan CJ (1997) Vascular effects of statins in stroke. Stroke 28:2315-2320
9. Endres M, Laufs U, Huang Z, Nakamura T, Huang PL, Moskowitz MA, Liao JK (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA (in press)
10. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A (1994) Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89:2519-2524
11. Feinberg WM (1996) Primary and secondary stroke prevention. Curr Opin Neurol 9:46-52
12. Galis ZA, Sukhova G, Lark M, Libby P (1994) Increased expression of matrix metallo-proteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaque. J Clin Invest 94:2493-2503
13. Garg UC, Hassid A (1989) Nitric oxide-generating vasodilators and 8- bromo-cyclic guanosine monophosphate inhibits mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777
14. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
15. Hachinski V, Graffagnini C, Beaudry M, Bernier G, Buck C, Donner A, Spence JD, Doig G, Wolfe BM (1996) Lipids and stroke: a paradox resolved. Arch Neurol 53:303-308
16. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242
17. Huang Z, Huang PL, Ma JH, Meng W, Ayata C, Fishman MC, Moskowitz MA (1996) Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenauted by nitro-L-arginine. J Cereb Blood Flow Metab 16:981-987
18. Keidar S, Aviram M, Maor I, Oikine J, Brook JG (1994) Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptoractivity in macrophages: in vitro and in vivo studies. Br J Pharmacol 38:513-519
19. Laufs U, LaFata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97:1129-1135
20. Laufs U, La Fata V, Liao JK (1997) Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272:31725-31729
21. Lefer AM, Ma XL (1993) Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. Arterioscler Thromb 13:771-776
22. Levine GNJ, Keaney JF, Vita JA (1995) Cholesterol reduction in cardiovascular disease. N Engl J Med 332:512-521
23. Liao JK, Shin WS, Lee WY, Clark SL (1995) Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270:319-324
24. Libby P (1995) Molecular basis of acute coronary syndromes. Circulation 91:2844-2850
25. Morikawa E, Rosenblatt S, Moskowitz MA (1992) L-arginine dilates rat pial arterioles by nitric-oxide dependent mechanisms and increases blood flow during focal cerebral ischemia. Br J Pharmacol 107:905-907
26. Morikawa E, Huang Z, Moskowitz MA (1992) L-arginine decreases infarct size caused by middle cerebral artery occlusion in SHR. Am J Physiol 263:H1632-H1635
27. Munro E, Patel M, Chan P, Bretteridge L, Clunn G, Gallagher K, Hughes A, Schachter M, Wolfe J, Sever P (1994) Inhibition of vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24:766-772
28. Iadecola C, Pellegrino DA, Moskowitz MA, Lassen NA (1994) Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 14:175-192
29. O'Driscoll G, Green D, Taylor RR (1997) Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within a month. Circulation 95:1126-1131
30. Packard CJ (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).Circulation 97:1440-1445
31. Prospective Studies Collaboration (1995) Cholesterol, diastolic blood pressure, and stroke: 13.000 strokes in 450,000 people in 45 prospective studies. Lancet 346:1647-1653
32. Radomski MW, Palmer RM, Moncada S (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87:5193-5197
33. Roussow JE (1995) Lipid-lowering interventions in angiographic trials. Am J Cardiol 76:86C-92C
34. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L,Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction on patients with average cholesterol levels. Cholesterol and recurrent events trial inverstigators. N Engl J Med 335:1001-1009
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Mac Farlane PW, McKillop JH, Pckard CJ, for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
36. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s). Lancet 344:1383-1389
37. Tell GS, Crouse JR, Furberg CD (1988) Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis: a review. Stroke 19:423-430
38. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Bodccuzzi SJ, Cedarholm JC, Alexander RW (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332:481-487
39. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP (1994) Enhanced endothelial adhesiveness in hypercholesterolenia is attenuated by L-arginine. Circulation 89:2176-2182
40. Walters D, Higginson L, Gladstone P (1994) Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89:959-968
41. West Scotland Coronary Prevention Study (1996) Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348:1339-1342
42. Yusuf F, Witters J, Friedma L (1988) Overview of results of randomized clinical trials in heart disease. II unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. J Am Med Assoc 260:2259-2263